4 Results for "

PD325901

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "PD325901" in MCE Product Catalog:

159
159 Cited Publications
Cat. No.: HY-10254
CAS No.: 391210-10-9
Purity:  99.95%
Synonyms: PD0325901; PD325901
Target:  

MEK Autophagy Apoptosis

Research Areas:  

Cancer

Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Ki app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10254G
CAS No.: 391210-10-9
Synonyms: PD0325901 (GMP); PD325901 (GMP)
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor .
loading...
    loading...
Cat. No.: HY-108790
CAS No.: 1211327-92-2
Synonyms: Peginterferon β-1a
Target:  

Apoptosis

Research Areas:  

Neurological Disease Cancer

Peginterferon beta-1a (Peginterferon β-1a) is the first pegylated interferon beta-1a molecule. Peginterferon beta-1a induces cancer cells apoptosis and shows anti-tumor activities in nude mice models. Peginterferon beta-1a can be used for the research of cancer and multiple sclerosis (RMS) .
loading...
    loading...
Cat. No.: HY-10254R
CAS No.: 391210-10-9
Synonyms: PD0325901 (Standard); PD325901 (Standard)
Research Areas:  

Cancer

Mirdametinib (Standard) is the analytical standard of Mirdametinib (HY-10254). This product is intended for research and analytical applications. Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Kiapp of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .
loading...
    loading...